Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Has Consensus Target Price of $41.80 According to Brokerages

Posted by George Bondi on Nov 6th, 2026

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $41.60.

Several equities analysts recently commented on the stock. UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. Mizuho set a $43.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday. Weiss Ratings upgraded shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th. Finally, Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th.

Get Our Latest Stock Report on SNDX

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

Positive Sentiment: Syndax reported that 19 Revuforj (revumenib) and Niktimvo abstracts were accepted for ASH 2026, including seven oral presentations. The data cover multiple leukemia settings and could provide pipeline catalysts. ASH abstract announcement
Positive Sentiment: HC Wainwright reiterated its Buy rating and $36 target, with small increases to its Q4 2026 and 2029–30 earnings estimates. The firm’s long-range forecasts anticipate a return to profitability, though that remains a forward-looking projection. HC Wainwright estimates
Neutral Sentiment: Syndax named Aaron A. Ondrey as CFO and scheduled an investor event for December 14. These announcements provide company updates but do not, by themselves, signal a change in business performance. CFO transition Investor event announcement
Negative Sentiment: HC Wainwright lowered its FY2027 EPS estimate to a loss of $1.36 per share from a loss of $0.79, and changed its FY2028 estimate from a profit to a loss. Separately, Syndax’s latest reported quarterly loss per share missed estimates, despite revenue beating expectations and rising year over year. Pomerantz also said it is investigating investor claims, adding a potential legal overhang; the announcement provided no details about the claims. Pomerantz investigation announcement

Syndax Pharmaceuticals Trading Down 10.3%

SNDX stock opened at $9.37 on Tuesday. The company has a quick ratio of 6.44, a current ratio of 4.69 and a debt-to-equity ratio of 38.95. Syndax Pharmaceuticals has a twelve month low of $9.29 and a twelve month high of $25.59. The stock has a 50-day simple moving average of $16.54 and a two-hundred day simple moving average of $20.07.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). Syndax Pharmaceuticals had a negative return on equity of 804.38% and a negative net margin of 72.32%. The firm had revenue of $83.30 million during the quarter, compared to analysts’ expectations of $81.38 million. During the same period in the previous year, the company posted ($0.70) earnings per share. The company’s quarterly revenue was up 81.9% compared to the same quarter last year. As a group, sell-side analysts predict that Syndax Pharmaceuticals will post -2.08 EPS for the current year.

Insider Activity

In related news, Director Dennis Podlesak sold 8,000 shares of the stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the sale, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Allworth Financial LP bought a new stake in Syndax Pharmaceuticals during the second quarter valued at approximately $26,000. Sterling Capital Management LLC grew its stake in Syndax Pharmaceuticals by 846.6% in the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock worth $56,000 after buying an additional 2,650 shares in the last quarter. Nykredit A S bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $72,000. Integrated Wealth Concepts LLC bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $73,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth $86,000.

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.